Multiprotease therapeutics for chronic pain

ABSTRACT

The invention includes Clostridial neurotoxin derivatives containing at least two light chain endopeptidase domains, and nucleic acids encoding such Clostridial neurotoxin derivatives. In preferred embodiments, the invention includes methods and compositions for the treatment of inflammatory disorders (such as arthritis); chronic pain, such as neuropathic pain and inflammatory pain through the use of such Clostridial neurotoxin derivatives, including those derived from an intact BoNT/A having an LC/E-derived endopeptidase joined to the LC/A endopeptidase.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority pursuant to 35 U.S.C. §119(e) to provisional patent application No. 61/920,053, filed Dec. 23, 2013.

REFERENCE TO A SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 25, 2014, is named A-05047_SL.txt and is 132,759 bytes in size.

BACKGROUND

The present invention is drawn to methods and composition involving Clostridial neurotoxin derivatives having an enhanced ability to disrupt exocytosis of pain and/or inflammatory mediators from nociceptors or inducers of inflammation, thus preventing pain.

Botulinum neurotoxin (BoNT) serotypes A-G, produced by Clostridium botulinum, are the most potent poisons known due to specifically blocking the release of acetylcholine from peripheral nerves by proteolytically cleaving SNARE (“Soluble NSF Attachment Protein Receptors”) proteins, which mediate the fusion of the synaptic vesicle with the cell membrane, and are thus essential for Ca²⁺-stimulated exocytosis of neurotransmitters and pain peptides from the neuron.

The ability of Clostridial toxins such as, e.g., Botulinum neurotoxins (BoNTs) (including the BoNT serotypes BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F and BoNT/G, as well as tetanus toxin TeTx) to inhibit neuronal transmission are being exploited in a wide variety of therapeutic and cosmetic applications, see e.g., Ward A B and Barnes M P, CLINICAL USERS OF BOTULINUM TOXINS (Cambridge University Press, Cambridge 2007). As an example, the BoNT/A-derived agent BOTOX® has been used in one or more countries for each the following indications: achalasia, adult spasticity, anal fissure, back pain, blepharospasm, bruxism, cervical dystonia, essential tremor, glabellar lines or hyperkinetic facial lines, headache, hemifacial spasm, hyperactivity of bladder, hyperhidrosis, juvenile cerebral palsy, multiple sclerosis, myoclonic disorders, nasal labial lines, spasmodic dysphonia, strabismus and VII nerve disorder.

There are Clostridial toxins other than the C. botulinum- and C. tetanus-derived toxins; these include, without limitation, the toxins of C. perfringins, C. septicum, C. difficile, C. spiroforme, C. butyricum and C. barati. However, it will be understood that in this specification a reference to “Clostridial toxins” or a similar reference, concerns the neurotoxins of C. botulinum subtypes and C. tetani subtypes, unless specifically or contextually indicated otherwise.

In addition, Clostridial toxin therapies are used or have been proposed for treating conditions including, without limitation,

a) neuromuscular disorders, see e.g., Kei Roger Aoki et al., Method for Treating Neuromuscular Disorders and Conditions with Botulinum Toxin Types A and B, U.S. Pat. No. 6,872,397 (Mar. 29, 2005); Rhett M. Schiffman, Methods for Treating Uterine Disorders, U.S. Patent Publication No. 2004/0175399 (Sep. 9, 2004); Richard L. Barron, Methods for Treating Ulcers and Gastroesophageal Reflux Disease, U.S. Patent Publication No. 2004/0086531 (May 7, 2004); and Kei Roger Aoki, et al., Method for Treating Dystonia with Botulinum Toxin C to G, U.S. Pat. No. 6,319,505 (Nov. 20, 2001);

b) eye disorders, see e.g., Eric R. First, Methods and Compositions for Treating Eye Disorders, U.S. Patent Publication No. 2004/0234532 (Nov. 25, 2004); Kei Roger Aoki et al., Botulinum Toxin Treatment for Blepharospasm, U.S. Patent Publication No. 2004/0151740 (Aug. 5, 2004); and Kei Roger Aoki et al., Botulinum Toxin Treatment for Strabismus, U.S. Patent Publication No. 2004/0126396 (Jul. 1, 2004);

c) pain, see e.g., Kei Roger Aoki et al., Pain Treatment by Peripheral Administration of a Neurotoxin, U.S. Pat. No. 6,869,610 (Mar. 22, 2005); Stephen Donovan, Clostridial Toxin Derivatives and Methods to Treat Pain, U.S. Pat. No. 6,641,820 (Nov. 4, 2003); Kei Roger Aoki, et al., Method for Treating Pain by Peripheral Administration of a Neurotoxin, U.S. Pat. No. 6,464,986 (Oct. 15, 2002); Kei Roger Aoki and Minglei Cui, Methods for Treating Pain, U.S. Pat. No. 6,113,915 (Sep. 5, 2000); Martin A. Voet, Methods for Treating Fibromyalgia, U.S. Pat. No. 6,623,742 (Sep. 23, 2003); Martin A. Voet, Botulinum Toxin Therapy for Fibromyalgia, U.S. Patent Publication No. 2004/0062776 (Apr. 1, 2004); and Kei Roger Aoki et al., Botulinum Toxin Therapy for Lower Back Pain, U.S. Patent Publication No. 2004/0037852 (Feb. 26, 2004);

d) muscle injuries, see e.g., Gregory F. Brooks, Methods for Treating Muscle Injuries, U.S. Pat. No. 6,423,319 (Jul. 23, 2002);

e) headache, see e.g., Martin Voet, Methods for Treating Sinus Headache, U.S. Pat. No. 6,838,434 (Jan. 4, 2005); Kei Roger Aoki et al., Methods for Treating Tension Headache, U.S. Pat. No. 6,776,992 (Aug. 17, 2004); and Kei Roger Aoki et al., Method for Treating Headache, U.S. Pat. No. 6,458,365 (Oct. 1, 2002); William J. Binder, Method for Reduction of Migraine Headache Pain, U.S. Pat. No. 5,714,469 (Feb. 3, 1998);

f) cardiovascular diseases, see e.g., Gregory F. Brooks and Stephen Donovan, Methods for Treating Cardiovascular Diseases with Botulinum Toxin, U.S. Pat. No. 6,767,544 (Jul. 27, 2004);

e) neurological disorders, see e.g., Stephen Donovan, Parkinson's Disease Treatment, U.S. Pat. No. 6,620,415 (Sep. 16, 2003); and Stephen Donovan, Method for Treating Parkinson's Disease with a Botulinum Toxin, U.S. Pat. No. 6,306,403 (Oct. 23, 2001);

g) neuropsychiatric disorders, see e.g., Stephen Donovan, Botulinum Toxin Therapy for Neuropsychiatric Disorders, U.S. Patent Publication No. 2004/0180061 (Sep. 16, 2004); and Steven Donovan, Therapeutic Treatments for Neuropsychiatric Disorders, U.S. Patent Publication No. 2003/0211121 (Nov. 13, 2003);

f) endocrine disorders, see e.g., Stephen Donovan, Method for Treating Endocrine Disorders, U.S. Pat. No. 6,827,931 (Dec. 7, 2004); Stephen Donovan, Method for Treating Thyroid Disorders with a Botulinum Toxin, U.S. Pat. No. 6,740,321 (May 25, 2004); Kei Roger Aoki et al., Method for Treating a Cholinergic Influenced Sweat Gland, U.S. Pat. No. 6,683,049 (Jan. 27, 2004); Stephen Donovan, Neurotoxin Therapy for Diabetes, U.S. Pat. No. 6,416,765 (Jul. 9, 2002); Stephen Donovan, Methods for Treating Diabetes, U.S. Pat. No. 6,337,075 (Jan. 8, 2002); Stephen Donovan, Method for Treating a Pancreatic Disorder with a Neurotoxin, U.S. Pat. No. 6,261,572 (Jul. 17, 2001); Stephen Donovan, Methods for Treating Pancreatic Disorders, U.S. Pat. No. 6,143,306 (Nov. 7, 2000);

g) cancers, see e.g., Stephen Donovan, Methods for Treating Bone Tumors, U.S. Pat. No. 6,565,870 (May 20, 2003); Stephen Donovan, Method for Treating Cancer with a Neurotoxin to Improve Patient Function, U.S. Pat. No. 6,368,605 (Apr. 9, 2002); Stephen Donovan, Method for Treating Cancer with a Neurotoxin, U.S. Pat. No. 6,139,845 (Oct. 31, 2000); and Mitchell F. Brin and Stephen Donovan, Methods for Treating Diverse Cancers, U.S. Patent Publication No. 2005/0031648 (Feb. 10, 2005);

h) otic disorders, see e.g., Stephen Donovan, Neurotoxin Therapy for Inner Ear Disorders, U.S. Pat. No. 6,358,926 (Mar. 19, 2002); and Stephen Donovan, Method for Treating Otic Disorders, U.S. Pat. No. 6,265,379 (Jul. 24, 2001);

i) autonomic disorders, see, e.g., Pankai J. Pasricha and Anthony N. Kalloo, Method for Treating Gastrointestinal Muscle Disorders and Other Smooth Muscle Dysfunction, U.S. Pat. No. 5,437,291 (Aug. 1, 1995);

j) as well as other disorders, see e.g., William J. Binder, Method for Treatment of Skin Lesions Associated with Cutaneous Cell-proliferative Disorders, U.S. Pat. No. 5,670,484 (Sep. 23, 1997); Eric R. First, Application of Botulinum Toxin to the Management of Neurogenic Inflammatory Disorders, U.S. Pat. No. 6,063,768 (May 16, 2000); Marvin Schwartz and Brian J. Freund, Method to Reduce Hair Loss and Stimulate Hair Growth, U.S. Pat. No. 6,299,893 (Oct. 9, 2001); Jean D. A. Carruthers and Alastair Carruthers, Cosmetic Use of Botulinum Toxin for Treatment of Downturned Mouth, U.S. Pat. No. 6,358,917 (Mar. 19, 2002); Stephen Donovan, Use of a Clostridial Toxin to Reduce Appetite, U.S. Patent Publication No. 2004/40253274 (Dec. 16, 2004); and Howard I. Katz and Andrew M. Blumenfeld, Botulinum Toxin Dental Therapies and Procedures, U.S. Patent Publication No. 2004/0115139 (Jun. 17, 2004); Kei Roger Aoki, et al., Treatment of Neuromuscular Disorders and Conditions with Different Botulinum, U.S. Patent Publication No. 2002/0010138 (Jan. 24, 2002); and Kei Roger Aoki, et al., Use of Botulinum Toxins for Treating Various Disorders and Conditions and Associated Pain, U.S. Patent Publication No. 2004/0013692 (Jan. 22, 2004).

Table 2, below, provides the amino acid sequences of isotypes of various currently known botulinum-related (BoNT and TeTX) Clostridial toxins. These toxins possess a minimum of approximately 35% amino acid identity with each other and share the same general functional domain organization and overall structural architecture. The naturally-occuring Clostridial toxins are each translated as a single chain polypeptide of approximately 150 kDa that is subsequently cleaved by proteolytic scission within a disulfide loop by a naturally-occurring protease, such as, e.g., an endogenous Clostridial toxin protease or a naturally-occurring protease produced in the environment. This post-translational processing yields a mature di-chain molecule comprising an approximately 50 kDa light chain (LC) and an approximately 100 kDa heavy chain (HC) held together by a single inter-chain disulfide bond and noncovalent interactions.

Each mature di-chain Clostridial toxin molecule comprises three functionally distinct domains: 1) an enzymatic domain located in the LC that includes a metalloprotease region containing a zinc-dependent endopeptidase activity which specifically targets one or more SNARE proteins that mediate the fusion of the synaptic vesicle with the cell membrane; 2) a translocation domain contained within the amino-terminal half of the H chain (termed “H_(N)”) that facilitates release of at least the LC chain of the toxin from an endosome into the cytoplasm of the target cell; and 3) a binding domain found within the carboxyl-terminal half of the H chain (H_(C)) that determines the binding activity and binding specificity of the toxin.

The H_(C) comprises H_(CN) and H_(CC) sub-domains (the N- and C-terminal portions of H_(C), respectively). There is now substantial evidence that most or all BoNT/X toxins bind a target cell using a “dual receptor”, wherein the H_(C) portion of the toxin comprising both H_(CN) and H_(CC) subdomains binds certain cell surface gangliosides and a protein receptor (perhaps glycosylated); binding of the protein receptor facilitates the internalization of the toxin within the cell. By “X” is meant any serotype of botulinum toxin. Although the term “BoNT/X” is generally used to indicate subtypes of botulinum toxin, the term may also include TeTX regions thereof. H_(CC) binds the receptor complex located at the surface of the target cell.

It will be understood that there exist strains or subtypes of each serotype of these toxins; these may vary somewhat in their amino acid sequences, particularly (but not exclusively) in non-critical regions (so called “variable” regions) without a substantial change in the identity or activity characteristic of the indicated toxin or toxin domain.

In Table 1 below, the standard one-letter and three letter amino acid codes are provided:

TABLE 1 Amino Acid Three letter code One letter code alanine Ala A arginine Arg R asparagine Asn N aspartic acid Asp D asparagine or Asx B aspartic acid cysteine Cys C glutamic acid Glu E glutamine Gln Q glutamine or glutamic Glx Z acid glycine Gly G histidine His H isoleucine Ile I leucine Leu L lysine Lys K methionine Met M phenylalanine Phe F proline Pro P serine Ser S threonine Thr T tryptophan Try W tyrosine Tyr Y valine Val V

TABLE 2 Clostridial Toxin Reference Sequences and Regions (identified from amino to carboxy direction; amino acid number to amino acid number) Toxin SEQ ID NO: LC H_(N) H_(C) BoNT/A 7 M1-K448 A449-K871 N872-L1296 BoNT/B 8 M1-K441 A442-S858 E859-E1291 BoNT/C 9 M1-K449 T450-N866 N867-E1291 1 BoNT/D 10 M1-R445 D446-N862 S863-E1276 BoNT/E 11 M1-R422 K423-K845 R846-K1252 BoNT/F 12 M1-K439 A440-K864 K865-E1274 BoNT/G 13 M1-K446 S447-S863 N864-E1297 TeNT 14 M1-A457 S458-V879 I880-D1315

Those of ordinary skill in the art recognize that Clostridial subtype toxin variants may exist in nature, having variations in the amino acid sequences shown above (or in the nucleotide sequences encoding these amino acid sequences). As used herein, the term “naturally-occurring Clostridial domain variant” means any Clostridial domain (endopeptidase, translocation, and/or binding domains) produced by a naturally-occurring process, including, without limitation, Clostridial domain isoforms produced from alternatively-spliced transcripts, Clostridial domain isoforms produced by spontaneous mutations and Clostridial domain subtypes. As used herein, a naturally-occurring Clostridial domain variant functions in substantially the same manner as the reference Clostridial domain on which the naturally-occurring Clostridial domain variant is based, and can be substituted for the reference Clostridial domain in any aspect of the present invention.

A naturally-occurring Clostridial domain variant may substitute one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, ten or more amino acids, 20 or more amino acids, 30 or more amino acids, 40 or more amino acids, 50 or more amino acids or 100 or more amino acids from the reference Clostridial domain on which the naturally-occurring Clostridial domain variant is based. A naturally-occurring Clostridial domain variant can also substitute at least 10 contiguous amino acids, at least 15 contiguous amino acids, at least 20 contiguous amino acids, or at least 25 contiguous amino acids from the reference Clostridial domain on which the naturally-occurring Clostridial domain variant is based, that possess at least 50% amino acid identity, 65% amino acid identity, 75% amino acid identity, 85% amino acid identity or 95% amino acid identity to the reference Clostridial domain on which the naturally-occurring Clostridial domain variant is based, so long as the biological or biochemical activity of the naturally-occurring Clostridial domain is substantially preserved. It will also be understood that conservative amino acid insertions and deletions can also be made so long as the characteristic function and identity of the domain is not substantially altered.

Due to the degeneracy of the genetic code, one of ordinary skill in the art will recognize that these amino acid sequences may be encoded by a finite set of different DNA molecules having different, but defined, nucleotide sequences. For example, degenerate nucleotide sequences encoding a given peptide or protein may have different codons adapted or selected to favor expression in a particular host cell. Using this information one can construct an expressible open nucleic acid reading frame for assembly of a nucleic acid molecule comprising any combination of these amino acid domain-encoding regions, either alone or with additional nucleic acid sequences, inserted into a suitable expression vector and subsequent expression within a chosen host cell. For example, International Patent Publication WO01/14570 discloses methods of making single-chain, cleavable recombinant modified or unmodified Clostridial neurotoxin derivatives and chimeric and hybrid forms thereof using such methods. Additional publications disclosing methods of making expressible recombinant neurotoxins and derivatives thereof include U.S. Pat. Nos. 5,989,545; 6,203,794; 6,395,513; U.S. Publication Numbers U.S. 2003/0166238; U.S. 2002/169942; U.S. 2004/176299; U.S. 2004/126397; U.S. 2005/035730; U.S. 2005/068494; U.S. 2006/011966; International Patent Applications WO95/32738; WO 99/55359; WO96/33273; WO98/07864; WO99/17806; WO98/07864; WO02/44199; WO02/40506, and U.S. patent application Ser. No. 13/644,386, filed Oct. 4, 2012. These and all other patents, patent publications, and non-patent publications cited in this patent application, whether or not specifically indicated as such, are hereby individually incorporated by reference as part of this specification.

The use of recombinant DNA techniques permits the construction of modified Clostridial neurotoxins having different or modified functional properties from the naturally-occurring toxin subtypes and strains thereof.

For example, altering the naturally-occurring amino acid sequence of the native neurotoxin light chain and/or adding a different therapeutic moiety permits the construction of transport proteins designed to carry a therapeutic agent within a neuron. See U.S. Pat. No. 6,203,794 (hereby incorporated by reference herein).

Altering the targeting (cell-binding) domain permits the toxin to be transported within pancreatic cells, such as acinar cells, thereby preventing secretion of activated digestive enzymes by such cells, See U.S. Pat. No. 6,843,998 (hereby incorporated by reference herein), or sensory afferent neurons, thereby preventing neurotransmitter, cytokine and pain peptide release and thus providing relief from pain; see U.S. Pat. No. 6,395,513 (hereby incorporated by reference herein.)

In addition, U.S. Pat. No. 7,422,877 (hereby incorporated by reference herein) discloses the creation of chimeric neurotoxin derivatives comprising, for example, the binding domain and the translocation domain (or modified versions thereof) of one neurotoxin subtype for example, BoNT/A, and the light chain region of another neurotoxin subtype, for example, BoNT/E. It will be seen that given the general structural homology between the neurotoxin subtypes, any combination of the three basic Clostridial neurotoxin domains, may be made in a single amino acid chain (or in cleaved di-chain molecules). Therefore, for example, a binding domain from any of neurotoxin subtypes A, B, C1, D, E, F, G, or TeTX may be independently combined with a translocation domain from neurotoxin subtypes A, B, C1, D, E, F, G, or TeTX, and further independently combined with a endopeptidase domain from any of neurotoxin subtypes A, B, C1, D, E, F, G or TeTX. This can be done, for example, by recombinant construction and expression of a single chimeric chain which is subsequently cleaved to yield the dichain toxin, or by separate expression of single H and L chains, which are then combined by, for example, creation of an interchain disulfide bond and subsequently purified. Furthermore, using such techniques, the activity of various domains may be altered (for example, mutations can be introduced in an LC domain to destroy the protease activity of the LC), or the naturally-occurring domains may be replaced with other moieties, as described elsewhere herein, where for example, the HC domain of BoNT/A (or a portion thereof) is mutated or deleted and a targeting ligand (TL) appended.

When discussing the three general neurotoxin domains of each Clostridial neurotoxin subtype (binding, translocation and endopeptidase), it will be understood that Clostridial neurotoxin research is a well-developed field, and the correlation of the amino acid sequences comprising each of these domains with their functions is well known. Reference to each of these terms (“translocation domain”, “binding domain”, and “protease”, “endopeptidase”, “LC” or “light chain” domain) shall be understood to include the corresponding domains contained in any of the amino acid sequences of Clostridial neurotoxin subtypes listed in SEQ ID NO: 7-14 as listed in Table 2, as well as conservatively modified and optimized variants of these sequences or domains within these sequences.

Additionally, the subdivision of these general domains into subdomains is also known. For example, the subdivision of binding domain H_(C) into subdomains H_(CN) (the amino-terminal portion of the domain, corresponding approximately to amino acids 871-1091 of BoNT/A) and H_(CC) (the carboxy-terminal portion of the H_(C) domain, corresponding approximately to amino acids 1092-1296 of BoNT/A) is also well known. See e.g., Lacy D B and Stevens R C, Sequence Homology and Structural Analysis of the Clostridial Neurotoxins, 1999, J. Mol. Biol. 291:1091-1104. Subdomain H_(CN) is highly conserved among botulinum toxin subtypes, however, little is known about its function. The H_(CC) subdomain is less conserved.

Additionally, the nucleotide and amino acid sequences of each of these domains and subdomains are known and have been disclosed in this specification, and therefore using this disclosure in combination with knowledge of the genetic code, nucleotide sequences encoding a protein to be expressed can be made. It would, of course, be a matter of routine for a person of ordinary skill in the art in view of this specification, to immediately envision other nucleotide sequences encoding the indicated polypeptides. Also, due to the redundancy of the genetic code, a finite number of nucleotide sequences are possible for each polypeptide. Further, it is clear that nucleic acids can be synthesized that comprise conservatively modified variants of these nucleotide sequences (or unique portions of them) in the region of homology containing no more than 10%, 8% or 5% base pair differences from a reference sequence.

Further, it will be understood that the amino acid sequences set forth in Table 2 and elsewhere in this specification or the associated sequence listing provide a full disclosure of any and all nucleotide sequences encoding these amino acid sequences and indicated regions thereof. A nucleotide sequence encoding an endopeptidase domain, translocation domain, or binding domain (including any subdomain) of a given neurotoxin subtype may respectively have 60% or greater, or 65% or greater, or 70% or greater, or 75% or greater, or 80% or greater, or 85% or greater, or 90% or greater, or 95% or greater, or 100% identity to any of such reference amino acid sequence regions listed in Table 2 or elsewhere.

Botulinum neurotoxins are expressed by Clostridial cells which also produce one or more non-toxin “neurotoxin associated proteins” or NAPs that non-covalently associate with the neurotoxin to form hemagglutinin complexes, also known as progenitor complexes. These NAPS help the neurotoxin resist protease degradation in the intestine when it is ingested in contaminated food.

The NAP proteins include three hemagglutinin (HA) proteins (HA1, HA2 and HA3), and a non-toxic, nonhemagglutinin protein (NTNH). BoNT types A2, E and F do not have the HA genes, and only produce a 12S (about 300 kDa) complex comprising BoNT and NTNH. “S” stands for Svedberg unit, a unit of centrifugal sedimentation rate. Types B, C and D produce 12S and 16S (about 500 kDa) complexes; the 16S complex includes BoNT, NTNH, HA1, HA2 and HA3. Type A1 has the 12S and 16S complexes plus a 19S complex of about 900 kDA, which may represent a dimer of 16S complexes.

Currently, BoNT/A1- and /B-hemagglutinin complexes have been approved for such clinical uses. The therapeutic benefits of BoNT/A1 complex are more persistent than that of BoNT/B due to its protease having a longer life-time in neurons.

As indicated above, BoNTs consist of a light chain-associated protease domain (LC) which is linked to a heavy chain (HC) through a single covalent disulphide bond and additional non-covalent bonds. A carboxy terminal (C-terminal) moiety of HC (H_(C)) binds to its specific acceptors expressed on various nerve types, including motor, autonomic and sensory neurons. When bound to a target cell the BoNT molecule is transported into vesicles by endocytosis; the amino terminal (N-terminal) half of HC (H_(N)) forms a channel that allows the LC to translocate from ‘endosomal-like’ membrane vesicles into the cytosol. Thereafter, the LC cleaves a specific SNARE protein substrate, thereby destroying the SNARE's ability to mediate vesicle-membrane fusion, and thus neurotransmitter, cytokine and pain peptide release from the cell.

The LCs of the various BoNT serotypes are similar, but not identical, and two different LCs may cleave different SNARE proteins, or cleave the same SNARE protein differently. For example, LC/A, LC/C, and LC/E cleave SNAP-25; LC/B, LC/D, LC/F, and LC/G cleave synaptobrevin-2 (VAMP-2); additionally, LC/C cleaves syntaxin, another SNARE protein which has been reported to be required for cell division. The LC of TeTx cleaves VAMP-2. The LCs of each serotype cleave their substrate at unique position in the molecule.

For example, the light chain of BoNT/A (LC/A) removes 9 amino acids from the C-terminus of SNAP-25, whereas the LC/E deletes a further 17 C-terminal residues and, thus, gives a more disruptive blockade of neuro-exocytosis by destabilising stable SNARE complexes (Meng et al., 2009; Wang et al., 2011). For example, the inhibition of neurotransmitter release by LC/A can usually be reversed by elevating Ca²⁺ influx, but not in the case of LC/E, presumably due to the greater destruction of the SNAP-25 substrate. However, despite the greater “robustness” of activity by LC/E, because LC/E induces only short transient neuromuscular paralysis, its clinical applications are limited.

It is highly desirable to create a therapeutic having new properties. For example, therapeutics in which two or more light chain endopeptidases derived from more than one serotype may be combined in a BoNT or TeTx derivative in which each light chain is active and recognizes a different amino acid sequence in its substrate SNARE protein may be designed to target conditions like chronic pain, chronic inflammatory conditions (including arthritis), and/or conditions involving cytokine release.

In one example, a therapeutic is designed combining the powerful protease of LC/E combined with the long-lasting action of LC/A. This is particularly important for improving the efficacy of BoNT/A for treating chronic pain, including tension headaches/migraines, and chronic inflammatory diseases such as arthritis because BoNT/A complex on its own has been found to be effective in some, but not all, such patients. See e.g., Naumann M. et al. (2008) ASSESSMENT: BOTULINUM NEUROTOXIN IN THE TREATMENT OF AUTONOMIC DISORDERS AND PAIN (AN EVIDENCE-BASED REVIEW): REPORT OF THE THERAPEUTICS AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY, Neurology 70:1707-1714 (hereby incorporated by reference herein). Blocking the exocytosis of pain-associated factors such as pain peptides and glutamate may prove useful in treating chronic pain, neuropathic pain and inflammatory conditions.

BoNT/A is unable to block the exocytotic release of pain-stimulating peptides [e.g. calcitonin gene-related peptide (CGRP) and substance P] from sensory neurons when elicited by activating TRPV1 (transient receptor potential vallinoid 1), a cation channel involved in the signalling of most forms of pain (Meng et al., 2007; Meng et al., 2009).

BoNT/E also fails to inhibit the capsasin-stimulated, TRPV1-mediated release of CGRP and substance P from sensory neurons, due to its cell surface acceptor (glycosylated synaptic vesicle protein 2A (SVP2A) and glycosylated SVP2B) being sparse or absent from the sensory neurons. However, a chimeric protein in which the H_(C) (receptor-binding domain) of BoNT/E is replaced by its counterpart from BoNT/A is able to block the release of these pain-mediating peptides, indicating that the BoNT/A cell surface receptor facilitates the endocytosis and delivery of LC/E into nociceptive C-fibres.

Once inside the neuron, the LC/E protease, removes 26 SNAP-25 amino acid residues, thus preventing the formation of a stable SNARE complex required for neuro-exocytosis (Meng et al., 2009). Although LC/A also cleaves SNAP-25, it only cleaves 9 amino acid residues, and the blockage of exocytotic activity is less complete and stable.

In order to make it practical to clinically exploit such an advantageous feature of the LC/E protease, it is desirable to greatly extend its duration of action.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic for the creation of a composite neurotoxin by creating a gene construct encoding an active LC/E joined to the N-terminus LC/A moiety of BoNT/A via a linker, to generate composite neurotoxin LC/E-BoNT/A, containing two active proteases.

FIG. 2A is a photo of SDS-PAGE electrophoresis showing the purification of the His6-tagged (“His6” disclosed as SEQ ID NO: 15) LC/E-BoNT/A construct by immobilized metal affinity chromatography (IMAC), using Talon® Superflow Resin (manufactured by Clonetech Laboratories, Inc.), a Co²⁺-charged agarose resin having a high degree of selectivity for the His6 tag (SEQ ID NO: 15).

FIG. 2B shows the absorbance and conductivity versus time in an elution profile of pooled LC/E-BoNT/A-containing IMAC fractions subsequently subjected to cation-exchange chromatography.

FIG. 3 is a photo of SDS-PAGE electrophoresis showing treatment of purified LC/E-BoNT/A with biotinylated thrombin to create double-chain toxin and remove the His6 (SEQ ID NO: 15) tag. The symbols + and − respectively indicate treatment with or without the agent dithiothreitol (DTT) to reduce the disulphide bond linking the LC/E-LC/A and HC/A chains.

FIG. 4 is a photo of Western blots in which serial dilutions of BoNT/A (upper gel) and LC/E-BoNT/A (lower gel) are assayed for their ability to cleave the SNARE protein SNAP-25 in cultured rat cerebellar granule neurons (CGNs).

FIG. 5 shows the duration of muscle paralysis in gastrocnemius muscle injected with LC/E-BoNT/A, BoNT/E or BoNT/A, in which the maximal tolerated dose (TD_(max)) is plotted versus length of time in days.

FIG. 6A is a photo of a Western blot in which serial dilutions of LC/E-BoNT/A are incubated with rat TGNs (trigeminal ganglion neurons) overnight, then the lysates assayed using anti-SNAP-25 and anti-syntaxin antibodies for the ability of LC/E-BoNT/A to cleave SNAP-25 (mainly to yield the 26 residue truncated SNAP-25 cleavage product produced by LC/E), but not syntaxin.

FIG. 6B is a dose response curve by LC/E-BoNT/A showing a) the cleavage of SNAP-25 and b) the inhibition of CGRP release evoked by 60 mM KCl or c) capsaicin in rat TGNs, and the failure of BoNT/A to significantly reduce CGRP release evoked by capsaicin in TGNs incubated with BoNT/A.

FIG. 7A is a plot of duration of anti-nociceptive activity in a rat model, the spared nerve injury (SNI) test, on animals treated with saline, BoNT/A or LC/E-BoNT/A, followed by placing the paw in a cold (4° C.) plate and measuring the time required for the rat to withdraw its paw from the plate, carried out from 4 days pre-surgery to about 21 days post surgery.

FIG. 7B is a plot of duration of anti-nociceptive activity in a rat model, the spared nerve injury (SNI) test, on animals treated with saline, BoNT/A or LC/E-BoNT/A, followed by measuring the induced allodynia by sensitivity to application of calibrated von Frey hairs onto the plantar surface of the hind paw, carried out from 4 days pre-surgery to about 21 days post surgery.

FIG. 8A is a schematic of a dual-protease polypeptide of the present invention. This polypeptide inactivates two different SNARE proteins: VAMP by LC/B and SNAP-25 by LC/A. A synthetic LC/B gene is fused to the 5-terminus of BoNT/A via a linker sequence (encoding “DI” residues) to generate the composite neurotoxin LC/B-BoNT/A. The latter also contains two thrombin recognition sequences.

FIG. 8B SDS-PAGE gel stained by Coomassie blue illustrating the purification of His₆-tagged LC/B-BoNT/A by IMAC, using Talon® Superflow Resin (manufactured by Clonetech Laboratories, Inc.).

FIG. 8C SDS-PAGE of IMAC-purified LC/B-BoNT/A following treatment with biotinylated thrombin to create di-chain (DC) toxin. The symbols + and − respectively indicate treatment with or without the reducing agent dithiothreitol (DTT).

FIG. 8D shows a Western blot of an SDS-PAGE gel in which serial dilutions of LC/B-BoNT/A are incubated with rat CGNs at 37° C. for 24 h. The lysates are then assayed using anti-SNAP-25 and anti-VAMP 2 antibodies to monitor the toxin's cleavage of the two SNARE proteins SNAP-25 and VAMP 2. Syntaxin 1, probed by its specific antibody and unrecognized by either LC/B or LC/A, acted as an internal loading control.

FIG. 8E Dose response curves for LC/B-BoNT/A showing cleavage of SNAP-25 (rectangle) and, VAMP 2 (inverted triangle) at higher concentrations of the LC/B-BoNT/A toxin.

FIG. 9 is another example of the present invention in which a multi-SNARE cleaving therapeutic candidate has the ability to inactivate all three major types of SNARE proteins: SNAP-25 and syntaxin 1-3 by LC/C1 and VAMP1-3 by LC/D. DI is a linker between LC/D and LC/C1.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to methods and compositions related to therapeutic polypeptide molecules derived from botulinum neurotoxins. In particular, the molecules comprise at least two active endopeptidase domains derived from the light chains of different BoNT serotypes. Very preferably the endopeptidase domains recognize and cleave different amino acid sequences in their substrate. Especially preferably, the endopeptidase domains are derived from two or more BoNT serotypes, or a BoNT serotype and a TeTx LC.

The ability to combine a heavy chain from a selected BoNT with at least two different active Clostridial light chain endopeptidase domains provides engineered therapeutic molecules having enhanced and tailored properties. Such therapeutics are first exemplified by the design and creation of a gene construct encoding a composite of two different BoNT serotypes, and prokaryotic expression/purification of the recombinant protein displaying multiple and synergistic biological activities with therapeutic applications.

Blockage of exocytosis by such multi-endopeptidase therapeutics may have additive activities such as blocking the trafficking of pain-sensing receptors to the surface of sensory neurons. Thus, not only do such therapeutics inhibit the exocytosis of soluble synaptic factors, but may also inhibit the trafficking of proteins that are integral to the neural membrane.

In certain therapeutics not illustrated in the Examples section the naturally occurring binding domain may be altered so that the therapeutic is retargeted to a different or additional cell type. For example, in Aoki et al., U.S. Pat. No. 6,776,990 the binding region of BoNT is replaced with human cholecystokinin, or an analog thereof, thereby targeting the toxin (having only a single endopeptidase) to pancreatic acinar cells. Similarly, in U.S. patent application Ser. No. 13/644,386, filed Oct. 4, 2012, a targeting ligand replaces the naturally occurring binding domain in certain examples. In one such example a gene encoding the human interleukin-1 receptor antagonist (IL-1RA) is used to replace the naturally occurring H_(C) region or part thereof, thereby targeting cytokine-secreting cells.

The presently preferred molecule exemplifying the invention is based on a novel concept for creating nucleic acid constructs that express a protein comprising the LC of BoNT/E fused to the LC/A moiety of active recombinant BoNT/A using molecular biological methods. This unique molecule comprises LC/E-BoNT/A (shown in FIG. 1) which binds to neuronal BoNT/A acceptors (e.g. synaptic vesicle protein 2 and/or gangliosides), undergoes acceptor-mediated endocytosis and translocates to the cytosol, where the SNARE protein SNAP-25 is effectively cleaved, resulting in inhibition of neurotransmitter, cytokine and pain peptide release. By “effectively cleaved” is meant wherein the majority of SNAP-25 molecules have a sufficient number of amino acids cleaved to prevent the reversal of exocytotic blockade by elevating Ca⁺ influx; for example, such as results from cleavage of SNAP-25 by LC/E.

The above-noted constructs are preferably designed to contain a short sequence encoding specific amino acid residues, situated between HC and LC of /A, that are selectively recognised and cleaved by a thrombin protease, so the single-chain (SC) recombinant protein obtained can be converted to the di-chain (DC) form in vitro by exposure to thrombin.

Very preferably, the present invention is exemplified by LC/E linked to the LC/A moiety of BoNT/A via a two amino acid linker (for example, aspartic acid-isoluecine; DI), yielding a novel composite toxin. In experiments involving the exposure of sensory neurons to this construct, the proteases was shown to be delivered within the cultured neurons, and the attached LC/E was stabilised which, in turn, produced long-lasting neuroparalysis like LC/A.

Importantly, unlike LC/A, this long-acting molecule produced mainly proteolytic products characteristic of LC/E and blocked the release of pain-mediators evoked by capsaicin from rat cultured sensory neurons, due to the inability of /E-cleaved SNAP-25 to mediate neurotransmitter, cytokine and pain peptide release. Moreover, this composite protein proved more effective than LC/A alone in attenuating pain behaviour in a rat model of neuropathic pain (spared nerve injury-induced).

The exemplary chimeric molecule thus offers major advantages as a therapeutic for treatment of chronic pain: (a) a highly-desirable and greatly-extended life-time of the normally transiently-acting/E protease, by virtue of nerve terminal retention/stabilising motifs present in the attached LC/A; (b) predominant cleavage of SNAP-25 by the /E protease destabilises SNARE complexes and (c) inhibition of TRPV1-mediated exocytosis of pain peptides from sensory neurons. These new findings highlight the anti-nociceptive potential of this proprietary engineered protein which exhibits synergistic compounded effects. Its advantages over the first generation of natural BoNTs have been conclusively demonstrated and, thus, should lead to much improved therapeutics.

Because native BoNTs have only one protease domain, the innovative concept of delivering an extra LC—which either cleaves the same substrate at a different position (or another substrate)—not only significantly boosts its inhibitory properties but the additional stabilising influence of the original LC/A results in a surprising synergistic action, namely greatly extended duration of therapeutic benefit compared to BoNT/E.

In other examples, a different multi-endopeptidase therapeutic is exemplified by the construction of a LC/B-BoNT/A nucleic acid construct using the techniques employed for the construction of the LC/E-BoNT/A nucleic acid. Upon expression of the polypeptide encoded by the LC/E-BoNT/A open reading frame, and nicking of the thrombin sites, the resultant protein cleaves both SNAP-25 and VAMP-2. Cleavage of two SNARE proteins involved in the synaptic fusion ternary complex may result in more effective

EXAMPLES Example 1

A synthetic BoNT/A gene, having its codons optimised for enhanced expression in E. coli and three extra nucleotide (AAA) encoding Lys residue, was cloned into Nde I and Sal I sites of a prokaryotic expression vector pET29a(+) to yield pET-29a-BoNT/A.

pET-29a-BoNT/A was then further modified in order to provide the ability for controlled specific nicking and simultaneous removal of the hexahistadine (His6 (SEQ ID NO: 15)) tag encoded by the pET-29a cloning vector. A nucleotide sequence encoding a thrombin cleavage sites was engineered into the nucleic acid region encoding the HC/LC loop of the toxin. This is shown below in both nucleic acid and amino acid form, as SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Modified BoNT/A  nucleotide sequence(SEQ ID NO: 1) and its encoded amino acid sequence (SEQ ID NO: 2)                           Thrombin cleavage site                                               

C  V  R  G  I  I  T  S  K  T  K  S  L  V  P  R  G  S  N  K  A  L  N  D  L  C TGTGTCCGCGGTATTATCACCAGCAAAACCAAATCCTTGGTGCCCCGCGGCTCTAACAAGGCGCTCAATGATTTATGC

Additionally, an additional thrombin site was inserted between the regions encoding the HC/A and His6 (SEQ ID NO: 15) regions of the expressed protein. This is shown below in both nucleic acid and amino acid form, as SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

Nucleotide sequence fused to the 3′ end of BoNT/A gene (SEQ ID NO: 3) and its encoded amino acid sequence (SEQ ID NO: 4)                Thrombin cleavage site 1                        

K  V  D  K  L  L  V  P  R  G  S  K  L  Q  L  E  H  H  H  H  H  H  * AAAGTCGAC AAGCTT CTGGTACCGCGCGGCAGCAAACTGCAG CTCGAGCACCACCACCACCACCACTGA 1    Sal I HindIII                     Pst I Xho I

The nucleotide sequence provided above contains the following regions, from left to right, respectively:

a) nucleotides 1-3: AAA codon inserted encoding additional Lys to provide an optional trypsin cleavage site, in order to remove the C-terminal His6 (SEQ ID NO: 15);

b) single underline: Sal I restriction endonuclease site;

c) double underline: Hind III restriction endonuclease site d) bold: thrombin recognition sequence;

e) single underline: Pst I restriction endonuclease site;

f) double underline: Xho I restriction endonuclease site;

g) nucleotides 49-66: nucleotide region encoding a His6 (SEQ ID NO: 15) tag. The aligned amino acid sequences are displayed above the corresponding nucleotides. The arrow indicates the thrombin cleavage site, and the asterisk denotes the translational “stop” codon.

This nucleic acid construct, comprising the BoNT/A open reading frame described above, and comprising both SEQ ID NO: 1 and SEQ ID NO: 3, was termed pET29a-BoNT/A-2T.

A PCR product (amplicon) was amplified from a synthetic nucleic acid encoding the LC/E protease (residues 1-411), and two restriction sites (Nde I and Eco RV) were incorporated during the amplification at the 5′ and 3′ ends of the nucleic acid amplicon, respectively. This PCR amplicon was then digested by Nde I and Eco RV and cloned into pET29a(+) vector, also digested with Nde I and Eco RV. The resultant intermediate vector construct was named pET29a-LC/E.

The above-noted intact “single chain” open reading frame BoNT gene region of BoNT/A-2T was amplified by PCR using pET29a-BoNT/A-2T as a template with a pair of primers (a bacteriophage T7 terminal reverse primer and a forward primer containing an EcoRV restriction sequence upstream of the BoNT/A 5′ coding sequence). The resulting PCR amplicon was digested by EcoRV and Xho I enzymes, purified, and inserted into Eco RV- and Xho I-cleaved pET29a-LC/E plasmid. This final construct was called pET29a-LC/E-BoNT/A, and the open nucleic acid reading frame is disclosed as SEQ ID NO: 5, while the corresponding amino acid sequence is disclosed herein as SEQ ID NO: 6.

Example 2

For expression of LC/E-BoNT/A, the sequence-verified construct was transformed into E. coli strain BL21(DE3), and expressing of the target protein was induced using Studier's auto-induction medium (Studier, F. W., 41 Protein Expr. Purif. 207 (2005)). Partial purification (˜60%) of the His6 (SEQ ID NO: 15) tagged protein in the bacteria lysate was achieved with immobilised metal (Co²⁺) affinity chromatograph (IMAC), using Talon superflow resin. A major protein of Mr˜200 kDa is eluted by greater than or equal to 50 mM imidazole; this is demonstrated in FIG. 2A, which shows SDS-PAGE and Coomassie blue staining of the gel. Gel lanes are as follows: Lane 1: cleared lysate before application to IMAC column; Lane 2: the IMAC column flowthrough fraction; Lane 3: the IMAC column wash fraction; Lanes 4-9, fractions eluted using imidazole from the IMAC column.

The pooled IMAC eluted fractions were buffer-exchanged into 0.02 M sodium phosphate buffer (pH 6.5), and then further purified by loading onto a UNO-S1 cation exchange column, followed by washing with up to 150 mM NaCl, and then elution with a NaCl gradient; the toxin was eluted NaCl concentrations of equal to or greater than 220 mM. FIG. 2B shows the elution profile (absorbance at 280 nm) of the LC/E-BoNT/A single chain polypeptide as a function of time, with the increase in conductivity of the NaCl gradient superimposed. The arrow shows the location of the LC/E-BoNT/A-containing absorbance peak.

Example 3

After buffer-exchanging the eluted intact toxin into 25 mM HEPES/145 mM NaCl (pH 7.4), the purified single chain (“SC”) protein was stored at −80° C., and aliquots were taken for SDS-PAGE analysis. FIG. 3 shows the results of reducing (+) and non-reducing (−) SDS-PAGE and Western blotting analysis of the purified polypeptide, confirming that this purified protein was indeed expressed in a SC form, as revealed by a single band migrating with an apparent molecular weight of about 200 kDa. This band was seen in either the absence or presence of reducing agent. See e.g., lanes SC (−) and SC (+) of the Coomassie Brilliant Blue-stained gel photo of FIG. 3.

Nicking of this SC polypeptide was attempted by incubation with biotinylated thrombin (1 unit/mg of protein) at 22° C. for 3 hours; the thrombin protease is then removed by treating the sample with streptavidin agarose. A band having an apparent molecular weight of about 100 KDa appears after thrombin treatment of the protein in samples run on an SDS-PAGE gel under reducing conditions; the ˜200 KDa band is not seen under these conditions, but is present in gels run under non-reducing conditions, while the ˜100 KDa band is absent in these latter samples. See e.g., lanes DC (−) and DC (+) of the Coomassie Brilliant Blue-stained gel photo of FIG. 3.

The ˜100 KDa band is believed to represent both the LC/E-LC/A and the HC/A chains, which have similar sizes. The identities of the polypetides in this band are confirmed by Western blotting of SDS-PAGE gels run on nicked and unnicked LC/E-BoNT/A using antibodies specific against each of the postulated single chain polypeptides LC/E and BoNT/A.

As shown in FIG. 3, the nicked sample continues to migrate at ˜200 kDa in the absence of reducing agent, indicating that the inter-chain disulphide bond between LC/E-LC/A and HC/A was formed, and persists, in all of the samples as shown in the lanes of the Western blots marked (−) and developed using either anti-LC/E or anti-BoNT/A antibodies. Thus, SDS-PAGE and Western blotting under reducing and non-reducing conditions highlight the specific nicking at the loop region that occurs without degradation of the composite toxin. A slight difference in the mobility of the un-nicked and nicked protein is due to removal of the His6 (SEQ ID NO: 15) tag in the thrombin-treated samples; this was confirmed using a specific antibody against this tag. See the Western blot using the anti-His6 (SEQ ID NO: 15) antibody of FIG. 3, in which the His6 (SEQ ID NO: 15) tag is undetectable. This experiment therefore also demonstrated that thrombin protease can simultaneously nick the toxin between the linked cysteine residues of the disulphide bond between the HC and the first LC, and remove the His6 (SEQ ID NO: 15).

Example 4

Recombinantly-produced LC/E-BoNT/A and BoNT/A were each incubated overnight at 10-fold serially diluted concentrations from 0.01 pM to 1000 pM of toxin with cultured rat cerebellar granule neurons (CGNs). These cells are dissociated from the cerebella of 7-8-day-old rats and suspended at about 1×10⁶/ml in 3 parts of basal Eagle's medium and 1 part of 40 mM HEPES-NaOH, pH 7.3, 78.4 mM KCl, 37.6 mM D-glucose, 2.8 ml CaCl₂, 1.6 mM MgSO₄, and 1.0 mM NaH₂PO₄, as well as 1× N2 supplement, 1 mM L-glutamine, 60 units/ml penicillin, 60 μg/ml streptomycin, and 2% (v/v) horse dialyzed serum. An aliquot (1 ml) of this cell suspension is added to each of 16-mm-diameter poly-D-lysine coated well (i.e. 24-format) and cytosine-β-D-arabinofuranoside (40 μM) added after culturing for 20-24 h in 5% (v/v) CO₂; the neurons are maintained by replacement every 10 days with the same freshly prepared medium. Where specified, the neurons are exposed to either BoNT/A or LC/E-BoNT/A (0.2-μm filter sterilized) in culture medium for 24 h.

After 24 hours' incubation with BoNT/A or LC/E-BoNT/A protein, cells are then harvested and subjected to SDS-PAGE and Western blotting using an anti-SNAP-25 antibody recognising intact SNAP-25, as well as both LC/A-cleaved SNAP-25 and LC/E-cleaved SNAP-25. The SNARE protein syntaxin 1 was used as a positive internal loading control.

Western blotting was performed using anti-SNAP-25 antibody. As can be seen in FIG. 4, LC/E-BoNT/A was nearly as active as BoNT/A in cleaving intact SNAP-25, with significant cleavage occurring at concentrations of toxin above 1 pM in each case. Notably, as can be seen, treatment of CGNs with LC/E-BoNT/A also gives a LC/A cleavage product when below about 1 pM of toxin is used. This cleavage product (“SNAP-25_(A)”) appears to be substantially further cleaved to the cleavage product of LC/E (“SNAP-25_(E)”) by the co-delivered LC/E protease when the LC/E-BoNT/A toxin's concentrations are raised above about 0.01 nM (FIG. 4). These results suggest that the BoNT/A heavy chain translocation domain is capable of delivering both covalently-linked LC/A and LC/E proteases to the cytosol of CGNs, where the proteases remain active to cleave SNAP-25, thereby wholly or partially inactivating the SNARE protein.

Example 5

The specific neurotoxicity of LC/E-BoNT/A is determined by intraperitoneal injection into mice in the manner described in Maisey, E. A., et al., 177 EUR. J. BIOCHEM. 683-691(1988), hereby incorporated by reference. The lowest amount of toxin that kills 50% of mice within 4 days is defined as one minimal lethal dose (mLD50). The specific activity of the toxins can be expressed as the number of mLD50 units/mg of toxin.

The mLD50 of the LC/E-BoNT/A preparation is observed to be 0.7×10⁸. This specific activity is between that observed for recombinant BoNT/E (0.4×10⁸) and that observed for recombinant BoNT/A (2×10⁸). The duration of neuroparalytic action in vivo was assessed using a mouse digit abduction score (DAS) assay, described in e.g., Aoki, K. R., 39 TOXICON 1815-1820 (2001), hereby incorporated by reference.

Recombinant LC/E-BoNT/A is injected into mouse gastrocnemius muscle at a dose of 0.5 mLD₅₀ unit, which is the maximum tolerated dose that may be administered to the experimental animals without producing systemic symptoms. This dosage of LC/E-BONT/A caused paralysis for about 27 days; similar to the effect induced by 6 units of native BoNT/A; see FIG. 5. The long-lasting action of the LC/E-BONT/A protein compared to BoNT/E is apparently is due to the ability of the LC/A moiety in the fusion protein to stabilise the attached LC/E moiety; BoNT/E alone gives much shorter paralysis than other toxins; see the comparison of BoNT/E versus LC/E-BoNT/A in FIG. 5.

Example 6

The anti-nociceptive potential of the LC/E-BONT/A protein is examined using trigeminal ganglionic neurons (TGNs). These cells are a good model for this experiment due to their involvement in pain propagation and the fact that these cells in culture provide a good model for investigating the release of pain peptides (CGRP, SP) triggered by different stimuli; see e.g., Bacccaglini and Hogan, 80 PROC NATL ACAD SCI U.S.A. 594-598 (1983). Capsaicin, isolated from chili peppers, activates TRPV1, which is mainly expressed on the C-fibre of sensory neurons. Thus, the ability of the composite toxin to block the release of CGRP evoked by its agonist, capsaicin, should be a good indication of its inhibitory activity.

BoNT/A only removes 9 amino acid residues from the C terminus of the SNARE protein SNAP-25 (the “/A-truncated” SNAP-25 cleavage product), and does not affect the CGRP exocytosis elicited by capsaicin in TGNs. By contrast, the removal of 17 additional residues by the LC/E protease (resulting in the “/E-truncated” SNAP-25 cleavage product), blocks this capsaicin-stimulated release of CGRP; see e.g., Meng et al., 29 J NEUROSCI 4981-4992 (2009), hereby incorporated by reference.

Since the main SNAP-25 cleavage product of the long-acting toxin, LC/E-BoNT/A, is the “/E-truncated” SNAP-25 cleavage product, rather than the “/A-truncated” SNAP-25 cleavage product in CGNs (see FIG. 4), it is expected that LC/E-BoNT/A will block the release of the CGRP pain peptide.

Briefly, TGNs are dissected from postnatal day 5 Wistar rats after being deeply-anesthetized with intraperitoneal injection of Dolethal (50 mg/kg body weight). The tissue is placed in ice-cold L15 medium, and then washed twice in ice-cold sterile CMF-HBSS before centrifugation at 170 g for 1 minute. After chopping the tissue into small pieces and passing through 10-ml Falcon pipettes pre-coated with L15 medium, the tissue is incubated with shaking at 37° C. for 30 minutes in a 1:1 mixture of calcium- and magnesium-free Hanks Balanced Salt Solution (CMF-HBSS) containing 2.4 U/ml dispase II and 1 mg/ml collagenase I. The suspension is then gently triturated through 10-ml Falcon pipettes pre-coated with L15 medium until cloudy, before adding 1 mg/ml DNase I for 15 minutes.

Following centrifugation at 170 g for 5 minutes, the cell pellet is suspended and washed three times in culture medium [Ham's F12 solution (Sigma-Aldrich, St. Louis, Mo.) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin]. Cells are seeded onto 24-well plates precoated with poly-L-lysine (0.1 mg/ml) and laminin (20 μg/ml) in F12 medium supplemented with nerve growth factor (NGF) (50 ng/ml) and maintained in a CO₂ incubator at 37° C. After 24 hours (and every day thereafter) the culture supernatant is replaced with fresh culture medium containing the anti-mitotic agent cytosine-β-D-arabinofuranoside (10 μM).

After overnight incubation of rat TGNs at 37° C. with serial dilutions of LC/E-BoNT/A, the extent of cleavage is monitored by SDS-PAGE followed by Western blotting using an anti-SNAP-25 antibody capable of binding to intact as well as A-truncated and E-truncated products.

As shown in FIG. 6A, LC/E-BoNT/A gives a dose-dependent cleavage of SNAP-25 with mainly “/E-truncated” SNAP-25 cleavage products.

Additionally, as expected, the composite toxin blocks the release of CGRP by TGNs evoked by 60 mM KCl or capsaicin in a dose-dependent manner (FIG. 6B). Ca²⁺-dependent CGRP release is stimulated by treatment with 60 mM KCl in HBS (isotopically balanced with NaCl). For stimulation with capsaicin, stocks (1 mM) were prepared in ethanol or dimethyl sulfoxide, respectively, and diluted in BR-HBS to the required concentrations. In all cases, the final concentration of vehicle is kept at 0.1%; this is also included in BR-HBS when measuring basal efflux.

Cells were stimulated with K⁺ or capsaicin and release of CGRP monitored for 30 min. To determine the amounts of CGRP released, 0.1 ml of sample were added to 96-well plates coated with a monoclonal antibody against CGRP, and enzyme immunoassay was performed following instructions for the kit.

The results show the ability of the LC/E-BoNT/A polypeptide to inhibit the release of pain peptides from large dense-core vesicles, while similar treatment of cells with BoNT/A failed to inhibit the release of CGRP upon the activation of the TRPV1 cation channel. See FIG. 6B.

Example 7

The anti-nociceptive activity of LC/E-BoNT/A was evaluated in a rat model of persistent peripheral neuropathic pain, namely the spared nerve injury (SNI) assay. This model is based upon the observation that virtually all neuropathic pain (except the special case of phantom limb pain, caused by complete lesion by amputation) results from a partial nerve injury. These neuropathic pains include diabetic neuropathy, postherpeutic neuralgia, toxic neuropathies, compression neuropathies and trauma, and are characterized by spontaneous lancinating, burning pain and shock-like pain as well as pain hypersensitivity including tactile allodynia, pin prick hyperalgesia and hyperpathia.

SNI surgery is conducted on anesthetized adult rats (such as Spague-Dawley rats), and involves the ligation and transection of two of the three terminal distal branches of the sciatic nerve (the tibial and common peroneal nerves), which leaving the third branch (the sural nerve) intact; see Decosterd, I. & Woolf, C. J., 87 PAIN 580-587 (2000) incorporated by reference herein. This model has the advantage of being both technically easy to perform, and subject to minimal variability in the degree of damage produced.

The toxins are injected into the plantar (palm) side of the distal hindlimb. The maximum intra-plantar dosages of LC/E-BoNT/A and BoNT/A (without affecting the locomotor function) are found to be 75 and 15 mouse LD50 units/kg, respectively. Rats with SNI show a long-lasting neuropathic pain-like behaviour in contrast to sham control rats (which are subjected to exposure of the sciatic nerve without any lesion).

The two models of neuropathic pain are tests of cold allodynia and mechanical allodynia. In the first test, that of cold hypersensitivity, the operated paw is contacted with a cold plate at 4° C., and the paw withdrawal duration is recorded at various time points, as shown in FIG. 7A. As a measure of cold hypersensitivity modulation, post-treatment values are expressed as a percentage of pre-treatment values.

As FIG. 7A shows, the cold hypersensitivity is efficiently reduced by LC/E-BoNT/A for 2 weeks after treatment (P<0.001 compared to saline-treated), particularly for the first 10 days. The anti-nociceptive effect of LC/E-BoNT/A is significantly greater than that induced by BoNT/A (P<0.05 at 5 and 7 days after injection). No cold-induced allodynia is seen in sham controls, whether given toxin or saline.

In the second test, mechanical allodynia is measured by placing the animal on an elevated wire grid, and stimulating the plantar surface of the treated paw with a set of von Frey hairs to determine how much sensory stimulation can be tolerated before pain (indicated by a brisk withdrawal of the paw) is detected. Von Frey hairs (or monofilaments) are calibrated to provide an approximately logarithmic scale of actual force, and a linear scale of perceived intensity. The mechanical threshold is expressed as 50% of the average minimum grams of force required to cause paw withdrawal.

As shown in FIG. 7B, mechanical thresholds is dramatically decreased by nerve injury (compare the sham controls with the SNI rats given only saline). Encouragingly, LC/E-BoNT/A begins to reverse this mechanical hypersensitivity within 2 days after injection, and a maximum of analgesic effect is seen at 7 days post-treatment. Significantly higher mechanical thresholds than the saline-treated rats are recorded from 3 to 10 days after injection (P<0.001 vs saline). Moreover, even though treatment with BoNT/A induces a modest increase of post-injury mechanical thresholds, LC/E-BoNT/A is found to be significantly more effective (P<0.05).

Neither toxin nor saline affected pain behaviour triggered by cold and mechanical stimuli when administered into sham animals (FIG. 7A, B). LC/E-BoNT/A proved much more effective than BoNT/A in reducing cold withdrawal duration (FIG. 7A) and especially, increasing mechanical withdrawal threshold (FIG. 7B). Importantly, injection of LC/E-BoNT/A into rats with SNI normalised sensitivity to cold and mechanical stimuli at days 3 and 7 to values similar to those of all the sham controls. In summary, LC/E-BoNT/A induces potent anti-nociceptive effects in rat models of chronic neuropathic pain.

Example 8

The composite synthetic neurotoxin open reading frame LC/E-BoNT/A gene sequence and its encoded amino acids (SEQ ID NO: 5 and 6, respectively) provided below contains the following regions, respectively (identified with respect to the nucleotide residues): residues 1-1233, LC/E; residues 1240-5130, BoNT/A. The DNA sequence comprising nucleotides (1234-1239) is introduced as a linker and ensures the proper reading frame. The aligned amino acid sequences are displayed above the corresponding nucleotides. A thrombin protease recognition sequence is inserted into the loop between LC/A and HN/A; similarly, another thrombin site was engineered to have a cleavage sequence to the carboxy site of the BoNT/A gene; these allow simultaneous nicking and removal of the C-terminal His6 (SEQ ID NO: 15).

Composite neurotoxin gene (LC/E-BoNT/A) sequence and its encoded amino acids (SEQ ID NO: 5 AND 6)      M  P  K  I  N  S  F  N  Y  N  D  P  V  N  D  R  T  I  L  Y  I  K  P  G  G  C  Q    1 ATGCCTAAAATCAATTCGTTCAACTATAATGACCCGGTTAACGATCGCACGATCCTGTATATCAAGCCAGGTGGATGTCA   80       E  F  Y  K  S  F  N  I  M  K  N  I  W  I  I  P  E  R  N  V  I  G  T  T  P  Q  D   81 AGAATTTTATAAATCATTCAACATCATGAAAAATATTTGGATTATCCCGGAACGCAACGTGATCGGCACGACGCCTCAAG  160        F  H  P  P  T  S  L  K  N  G  D  S  S  Y  Y  D  P  N  Y  L  Q  S  D  E  E  K  161 ATTTICACCCGCCGACCTCCCTGAAAAATGGCGACAGTTCCTACTATGACCCGAATTATTTACAATCGGATGAAGAAAAA  240      D  R  F  L  K  I  V  T  K  I  F  N  R  I  N  N  N  L  S  G  G  I  L  L  E  E  L  241 GATCGTTTCCTCAAGATCGTCACGAAAATTTTCAACCGCATCAATAACAATCTGICCGGIGGCATCTTACTTGAGGAATT  320       S  K  A  N  P  Y  L  G  N  D  N  T  P  D  N  Q  F  H  I  G  D  A  S  A  V  E  I  321 ATCTAAAGCTAATCCGTATCTGGGGAACGATAATACCCCGGATAATCAGTTCCACATTGGCGATGCGAGCGCTGTGGAAA  400        K  F  S  N  G  S  Q  D  I  L  L  P  N  V  I  I  M  G  A  E  P  D  L  F  E  T  401 TTAAATTCAGCAACGGCAGTCAAGATATTCTTCTCCCAAACGTGATTATCATGGGGGCTGAACCTGATCTTTTCGAAACT  480      N  S  S  N  I  S  L  R  N  N  Y  M  P  S  N  H  G  F  G  S  I  A  I  V  T  F  S  481 AATAGTTCCAATATTICACTGCGCAATAATTATATGCCGTCGAACCATGGCTITGGCTCAATCGCAATTGTGACGTICTC  560       P  E  Y  S  F  R  F  N  D  N  S  M  N  E  F  I  Q  D  P  A  L  T  L  M  H  E  L  561 ACCTGAATATAGTITTCGTITTAACGACAACAGCATGAATGAATTTATCCAAGACCCGGCGCTGACTITGATGCATGAAC  640        I  H  S  L  H  G  L  Y  G  A  K  G  I  T  T  K  Y  T  I  T  Q  K  Q  N  P  L  641 TGATCCATAGCTTGCACGGCCTGTATGGCGCTAAAGGCATCACTACCAAATACACGATTACGCAAAAACAAAATCCCTTA  720      I  T  N  I  R  G  T  N  I  E  E  F  L  T  F  G  G  T  D  L  N  I  I  T  S  A  Q  721 ATCACCAACATCCGCGGCACCAACATTGAAGAATTTCTGACCTTCGGCGGAACGGATCTGAACATCATTACATCTGCCCA  800       S  N  D  I  Y  T  N  L  L  A  D  Y  K  K  I  A  S  K  L  S  K  V  Q  V  S  N  P  801 AAGCAACGACATCTATACCAATCTGITAGCAGATTATAAGAAAATCGCCAGCAAATTATCTAAAGTTCAGGICAGCAATC  880        L  L  N  P  Y  K  D  V  F  E  A  K  Y  G  L  D  K  D  A  S  G  I  Y  S  V  N  881 CGCTGITAAACCCGTATAAAGATGIGTTCGAAGCGAAATACGGCTIGGACAAAGACGCTAGIGGCATCTATTCCGTCAAT  960      I  N  K  F  N  D  I  F  K  K  L  Y  S  F  T  E  F  D  L  A  T  K  F  Q  V  K  C  961 ATTAATAAATTTAACGATATTTICAAAAAATTATATTCCTICACCGAATTTGATTTGGCCACCAAATTCCAGGTCAAATG 1040       R  Q  T  Y  I  G  Q  Y  K  Y  F  K  L  S  N  L  L  N  D  S  I  Y  N  I  S  E  G 1041 TCGTCAAACCTATATTGGCCAATACAAATATTTTAAACTGAGCAACCTGCTTAATGATTCCATCTACAATATTAGTGAAG 1120        Y  N  I  N  N  L  K  V  N  F  R  G  Q  N  A  N  L  N  P  R  I  I  T  P  I  T 1121 GTTACAATATTAATAACCTGAAAGTTAACTTTCGTGGGCAAAATGCGAATCTGAACCCCCGCATCATTACACCCATCACG 1200      G  R  G  L  V  K  K  I  I  R  F  D  I  M  P  F  V  N  K  Q  F  N  Y  K  D  P  V 1201 GGCCGTGGGTTGGTCAAAAAAATTATTCGCTTTGATATCATGCCGTTCGTAAACAAACAGTTCAACTATAAAGACCCAGT 1280       N  G  V  D  I  A  Y  I  K  I  P  N  A  G  Q  M  Q  P  V  K  A  F  K  I  H  N  K 1281 CAACGGCGTGGACATTGCCTATATCAAAATCCCGAATGCGGGTCAAATGCAGCCCGTGAAAGCATTTAAAATCCATAACA 1360        I  W  V  I  P  E  R  D  T  F  T  N  P  E  E  G  D  L  N  P  P  P  E  A  K  Q 1361 AAATTTGGGTGATCCCGGAGCGCGATACGTTCACGAACCCGGAAGAAGGAGATTTAAACCCACCGCCTGAGGCTAAACAG 1440      V  P  V  S  Y  Y  D  S  T  Y  L  S  T  D  N  E  K  D  N  Y  L  K  G  V  T  K  L 1441 GTCCCGGTGTCTTACTATGATAGCACATACCTGAGTACCGACAATGAAAAGGACAACTACCTGAAAGGTGTTACCAAACT 1520       F  E  R  I  Y  S  T  D  L  G  R  M  L  L  T  S  I  V  R  G  I  P  F  W  G  G  S 1521 GHTCGAGCGCATTTATTCGACAGATCTCGGTCGCATGTTGCTGACTTCTATTGTGCGCGGCATTCCGITTTGGGGIGGTA 1600        T  I  D  T  E  L  K  V  I  D  T  N  C  I  N  V  I  Q  P  D  G  S  E  R  S  E 1601 GCACCATCGATACAGAACTCAAAGTGATTGACACCAACTGCATCAATGTGATTCAGCCTGATGGGAGCTACCGGTCCGAA 1680      E  L  N  L  V  I  I  G  P  S  A  D  I  I  Q  F  E  C  K  S  F  G  H  E  V  L  N 1681 GAGCTTAACCTCGTAATCATTGGCCCGAGCGCGGATATTATCCAATTCGAATGTAAATCTTTTGGGCATGAAGTCCTGAA 1760       L  T  R  N  G  Y  G  S  T  Q  Y  I  R  F  S  P  D  F  T  F  G  F  E  E  S  L  E 1761 TCTGACGCGGAATGGCTATGGATCGACGCAGTATATTCGTITTICTCCAGATTICACATTIGGATTTGAAGAAAGCCTCG 1840        V  D  T  N  P  L  L  G  A  G  K  F  A  T  D  P  A  V  T  L  A  H  E  L  I  H 1841 AAGTTGATACGAACCCTCTTTTAGGCGCGGGAAAATTCGCGACGGACCCAGCGGTGACCTTGGCACATGAACTTATTCAT 1920      A  G  H  R  L  Y  G  I  A  I  N  P  N  R  V  F  K  V  N  T  N  A  Y  Y  E  M  S 1921 GCCGGGCATCGCTTGTATGGAATCGCCATTAACCCGAACCGTGTTTTCAAGGTGAATACGAACGCGTATTACGAGATGTC 2000       G  L  E  V  S  F  E  E  L  R  T  F  G  G  H  D  A  K  F  I  D  S  L  Q  E  N  E 2001 GGGCTTAGAAGTGTCCTTTGAAGAACTGCGCACGTTTGGCGGTCATGATGCAAAATTTATTGATAGTCTGCAAGAAAACG 2080        F  R  L  Y  Y  Y  N  K  F  K  D  I  A  S  T  L  N  K  A  K  S  I  V  G  T  T 2081 AATTTCGGCTGTACTATTACAATAAATTCAAAGACATTGCATCAACCTTAAACAAGGCGAAAAGCATTGTGGGTACCACG 2160      A  S  L  Q  Y  M  K  N  V  F  K  E  K  Y  L  L  S  E  D  T  S  G  K  F  S  V  D 2161 GCTAGCTTACAATATATGAAAAACGTTTTCAAAGAAAAATACCTCCTTAGCGAAGACACTTCCGGCAAATTCTCTGTCGA 2240       K  L  K  F  D  K  L  Y  K  M  L  T  E  I  Y  T  E  D  N  F  V  K  F  F  K  V  L 2241 TAAACTGAAATTTGATAAACTGTATAAAATGCTCACCGAGATCTACACAGAGGATAACTTTGTCAAATTCTTCAAGGTCT 2320        N  R  K  T  Y  L  N  F  D  K  A  V  F  K  I  N  I  V  P  K  V  N  Y  T  I  Y 2321 TGAATCGGAAAACCTATCTGAACTTCGATAAAGCCGTCTTTAAGATCAACATCGTACCGAAAGTTAACTACACCATCTAT 2400      D  G  F  N  L  R  N  T  N  L  A  A  N  F  N  G  Q  N  T  E  I  N  N  M  N  F  T 2401 GATGGCTTTAATCTGCGCAATACGAATCTGGCGGCGAACTTTAACGGCCAGAACACCGAAATCAACAACATGAACTTTAC 2480       K  L  K  N  F  T  G  L  F  E  F  Y  K  L  L  C  V  R  G  I  I  T  S  K  T  K  S 2481 TAAACTGAAAAATTTTACCGGCTTGTTTGAATTTTATAAGCTCCTGTGTGTCCGCGGTATTATCACCAGCAAAACCAAAT 2560           Thrombin cleavage site                   

       L  V  P  R  G  S  N  K  A  L  N  D  L  C  I  K  V  N  N  W  D  L  F  F  S  P 2561 CCTTGGTGCCCCGCGGCTCTAACAAGGCGCTCAATGATTTATGCATCAAGGTGAACAACTGGGACTTGTTTTTCTCTCCA 2640      S  E  D  N  F  T  N  D  L  N  K  G  E  E  I  T  S  D  T  N  I  E  A  A  E  E  N 2641 TCTGAAGATAATTTTACTAACGACTTGAACAAAGGAGAGGAAATTACTTCCGATACCAACATCGAAGCAGCGGAAGAGAA 2720       I  S  L  D  L  I  Q  Q  Y  Y  L  T  F  N  F  D  N  E  P  E  N  I  S  I  E  N  L 2721 TATTAGCCTGGATCTTATTCAACAATATTACCTGACCTTTAATTTTGATAACGAGCCTGAGAACATTTCCATTGAGAATC 2800        S  S  D  I  I  G  Q  L  E  L  M  P  N  I  E  R  F  P  N  G  K  K  Y  E  L  D 2801 TCAGCTCTGACATCATCGGCCAGCTGGAACTGATGCCGAATATCGAACGCTTTCCTAATGGAAAGAAATATGAATTGGAC 2880      K  Y  T  M  F  H  Y  L  R  A  Q  E  F  E  H  G  K  S  R  I  A  L  T  N  S  V  N 2881 AAATACACCATGTTCCACTATCTCCGCGCGCAGGAGTTTGAGCACGGCAAGTCTCGTATTGCTCTGACCAATTCGGTAAA 2960       E  A  L  L  N  P  S  R  V  Y  T  F  F  S  S  D  Y  V  K  K  V  N  K  A  T  E  A 2961 CGAAGCCCTTTTAAATCCTTCGCGTGTGTACACCTTTTTCTCAAGCGATTATGTTAAAAAAGTGAACAAGGCGACCGAAG 3040        A  M  F  L  G  W  V  E  Q  L  V  Y  D  F  T  D  E  T  S  E  V  S  T  T  D  K 3041 CGGCGATGTTTTTGGGATGGGTGGAACAACTGGTATATGACTTTACGGATGAAACTTCTGAAGTCTCGACCACCGACAAA 3120      I  A  D  I  T  I  I  I  P  Y  I  G  P  A  L  N  I  G  N  M  L  Y  K  D  D  F  V 3121 ATTGCCGATATTACCATTATCATTCCCTATATTGGCCCTGCACTGAACATTGGTAACATGCTGTATAAAGATGATTTTGT 3200       G  A  L  I  F  S  G  A  V  I  L  L  E  F  I  P  E  I  A  I  P  V  L  G  T  F  A 3201 GGGCGCCCTGATCTTTTCAGGCGCTGTTATCCTGCTGGAATTTATCCCGGAAATCGCCATTCCAGTACTCGGTACCTTTG 3280        L  V  S  Y  I  A  N  K  V  L  T  V  Q  T  I  D  N  A  L  S  K  R  N  E  K  W 3281 CGCTGGTGTCCTATATCGCAAACAAAGTTTTGACTGTCCAGACGATCGACAACGCGCTCAGTAAACGTAACGAAAAATGG 3360      D  E  V  Y  K  Y  I  V  T  N  W  L  A  K  V  N  T  Q  I  D  L  I  R  K  K  M  K 3361 GATGAGGTGTATAAGTATATTGTTACCAACTGGCTCGCTAAAGTAAACACCCAGATTGACCTGATTCGCAAGAAGATGAA 3440       E  A  L  E  N  Q  A  E  A  T  K  A  I  I  N  Y  Q  Y  N  Q  Y  T  E  E  E  K  N 3441 AGAAGCGCTGGAAAACCAAGCAGAAGCGACCAAAGCTATTATCAACTATCAATATAACCAGTACACAGAGGAAGAAAAGA 3520        N  I  N  F  N  I  D  D  L  S  S  K  L  N  E  S  I  N  K  A  M  I  N  I  N  K 3521 ATAACATCAACTTCAACATCGACGACTTATCTTCAAAGCTGAATGAATCTATTAACAAAGCGATGATTAATATTAACAAG 3600      F  L  N  Q  C  S  V  S  Y  L  M  N  S  M  I  P  Y  G  V  K  R  L  E  D  F  D  A 3601 TTCTTGAACCAATGTAGTGTCAGCTATCTGATGAACTCGATGATCCCATATGGTGTGAAACGTCTGGAAGACTTCGATGC 3680       S  L  K  D  A  L  L  K  Y  I  Y  D  N  R  G  T  L  I  G  Q  V  D  R  L  K  D  K 3681 AAGCCTTAAAGATGCCCTTCTGAAGTATATTTACGATAATCGCGGAACTCTTATTGGCCAAGTGGATCGCTTAAAAGATA 3760        V  N  N  T  L  S  T  D  I  P  F  Q  L  S  K  Y  V  D  N  Q  R  L  L  S  T  F 3761 AAGTCAACAACACGCTGAGTACAGACATCCCTTTTCAGCTGTCTAAATATGTGGACAATCAGCGCCTGCTGTCCACGTTT 3840      T  E  Y  I  K  N  I  I  N  T  S  I  L  N  L  R  Y  E  S  N  H  L  I  D  L  S  R 3841 ACGGAATACATCAAAAACATCATCAACACTAGTATTCTGAACTTGCGTTACGAGAGTAACCATCTGATTGATCTGAGCCG 3920       Y  A  S  K  I  N  I  G  S  K  V  N  F  D  P  I  D  K  N  Q  I  Q  L  F  N  L  E 3921 TTACGCATCTAAAATCAACATCGGCTCGAAGGTGAACTTCGATCCTATCGACAAAAACCAGATTCAATTGTTCAACTTAG 4000        S  S  K  I  E  V  I  L  K  N  A  I  V  Y  N  S  M  Y  E  N  F  S  T  S  F  W 4001 AATCGTCAAAGATTGAAGTTATCTTAAAAAATGCGATTGTATATAATTCAATGTACGAAAATTTCTCTACGAGCTTTTGG 4080      I  R  I  P  K  Y  F  N  S  I  S  L  N  N  E  Y  T  I  I  N  C  M  E  N  N  S  G 4081 ATTCGTATTCCGAAATATTTCAACAGTATCTCTTTAAACAACGAGTATACTATCATCAATTGTATGGAGAATAACAGCGG 4160       W  K  V  S  L  N  Y  G  E  I  I  W  T  L  Q  D  T  Q  E  I  K  Q  R  V  V  F  K 4161 GTGGAAAGTGAGCCTTAACTATGGTGAAATCATCTGGACTCTGCAGGACACTCAAGAAATTAAACAACGCGTGGTGTTTA 4240        Y  S  Q  M  I  N  I  S  D  Y  I  N  R  W  I  F  V  T  I  T  N  N  R  L  N  N 4241 AATACTCACAGATGATTAACATCTCGGATTATATTAATCGCTGGATTTTTGTGACAATTACTAACAACCGGCTGAACAAC 4320      S  K  I  Y  I  N  G  R  L  I  D  Q  K  P  I  S  N  L  G  N  I  H  A  S  N  N  I 4321 AGCAAAATTTACATTAACGGTCGCCTGATCGATCAGAAACCAATCAGTAATCTCGGTAACATTCACGCATCGAATAATAT 4400       M  F  K  L  D  G  C  R  D  T  H  R  Y  I  W  I  K  Y  F  N  L  F  D  K  E  L  N 4401 CATGTTCAAACTGGATGGTTGTCGCGACACGCACCGTTACATTTGGATCAAATACTTCAATTTATTCGACAAAGAACTCA 4480        E  K  E  I  K  D  L  Y  D  N  Q  S  N  S  G  I  L  K  D  F  W  G  D  Y  L  Q 4481 ACGAAAAGGAGATTAAGGATCTTTATGACAATCAGTCTAATTCGGGTATTCTGAAAGACTTTTGGGGTGATTACCTTCAG 4560      Y  D  K  P  Y  Y  M  L  N  L  Y  D  P  N  K  Y  V  D  V  N  N  V  G  I  R  G  Y 4561 TACGATAAACCGTATTATATGTTAAACTTATATGATCCGAATAAATACGTTGACGTCAACAACGTTGGCATTCGTGGCTA 4640       M  Y  L  K  G  P  R  G  S  V  M  T  T  N  I  Y  L  N  S  S  L  Y  R  G  T  K  F 4641 TATGTATCTGAAAGGGCCGCGTGGCAGCGTGATGACCACTAACATTTACTTAAACTCCTCCCTCTATCGCGGTACTAAAT 4720        I  I  K  K  Y  A  S  G  N  K  D  N  I  V  R  N  N  D  R  V  Y  I  N  V  V  V 4721 TTATTATCAAGAAATATGCCTCTGGCAACAAGGACAATATCGTACGCAATAACGATCGCGTCTACATTAACGTGGTGGTG 4800      K  N  K  E  Y  R  L  A  T  N  A  S  Q  A  G  V  E  K  I  L  S  A  L  E  I  P  D 4801 AAGAATAAAGAATATCGTCTGGCGACCAATGCTAGTCAGGCGGGCGTGGAGAAAATTCTGTCTGCACTTGAAATCCCGGA 4880       V  G  N  L  S  Q  V  V  V  M  K  S  K  N  D  Q  G  I  T  N  K  C  K  M  N  L  Q 4881 TGTGGGTAATTTATCCCAGGTGGTTGTGATGAAAAGTAAAAATGACCAAGGGATCACCAATAAATGCAAAATGAATCTGC 4960        D  N  N  G  N  D  I  G  F  I  G  F  H  Q  F  N  N  I  A  K  L  V  A  S  N  W 4961 AAGATAACAACGGCAACGACATTGGTTTTATCGGCTTCCACCAATTCAATAATATCGCGAAACTGGTGGCCTCAAATTGG 5040      Y  N  R  Q  I  E  R  S  S  R  T  L  G  C  S  W  E  F  I  P  V  D  D  G  W  G  E 5041 TACAACCGTCAGATTGAGCGCAGCTCCCGCACTTTAGGCTGTAGCTGGGAGTTCATTCCGGTAGATGACGGTTGGGGAGA 5120                                Thrombin cleavage site                                        

      R  P  L  K  V  D  K  L  L  V  P  R  G  S  K  L  Q  L  E  H  H  H  H  H  H  * 5121 ACGCCCATTGAAAGTCGACAAGCTTCTGGTACCGCGCGGCAGCAAACTGCAGCTCGAGCACCACCACCACCACCACTGA  5199

This example of the present invention addresses at least two major problems presented by the state of the art. Firstly, it provides a long-lasting BoNT chimera which has broadened anti-nociceptive therapeutic potential. Secondly, it provides a long-lasting BoNT-derived therapeutic with unique potential for chronic pain therapy.

Management of chronic pain poses a major challenge for modern healthcare because sufferers represent over 20% of the adult population. A substantial proportion of the population do not respond to the commonly-used pain killers. Additionally, the increase in drug dependence and abuse linked to the profusion of prescription opiates, and the short half-lives of many analgesics in most cases originally prescribed for pain, makes the use of opioids and non-steroid anti-inflammatory drugs unattractive options.

Therapeutic uses of BoNT/A complex proved beneficial for some but not all migraine sufferers, due to a postulated interference with pain pathways. The failure of BoNT/A to attenuate neuronal firing elicited by a pain peptide or TRPV1 activation of C-fibres in situ and inability to block CGRP release from cultured neurons highlight that it is essential to develop long-lasting and more-widely effective forms.

A BoNT-derivative chimera of BoNT/A and BoNT/E enters TGNs successfully, and gives /E-like SNAP-25 cleavage products which, in turn, inhibits the release of pain mediators; however, its short duration of action limits clinical applications.

The present invention combines domains of at least two BoNTs of different serotypes together to produce novel therapeutics. This innovative strategy can be used to generate other chimeric multichain therapeutics, including constructs comprising multiple LCs from different BoNT serotypes to yield therapeutics having desired properties; for example, a multi-SNARE-cleaving toxin (cleaving different SNARE proteins) therapeutic, which can be constructed, for example, by attaching LC/C1 to BoNT/A instead of LC/E.

Example 9

In another example, a multi-endopeptidase construct was created by substituting the LC/E gene in LC/E-BoNT/A nucleic acid with a synthetic LC/B gene to create a final plasmid encoding LC/B-BoNT/A as a single open reading frame in a manner substantially similar to that described above.

For expression of LC/B-BoNT/A, the sequence-verified nucleic construct was transformed into E. coli strain BL21(DE3), and the resultant protein was expressed as described previously for LC/E-BoNT/A. Partial purification of the His₆-tagged toxin from the cleared bacteria lysate was achieved using an IMAC affinity separation step, using Talon superflow resin. A major protein of Mr˜200 k was eluted by ≧150 mM imidazole; this is demonstrated in FIG. 8B, which shows SDS-PAGE under reducing conditions and Coomassie blue staining of the gel. Gel lanes are as follows: Lanes 1: cleared lysate before application to IMAC column; 2: the IMAC column flowthrough fraction; 3: the IMAC column wash fraction; 4-8, fractions eluted using imidazole.

The pooled IMAC eluate was buffer-exchanged into 25 mM HEPES/145 mM NaCl (pH 7.4) and aliquots analysed by SDS-PAGE. FIG. 8C shows SDS-PAGE of the purified protein in which aliquots were electrophoresed under reducing (+) and non-reducing (−). Electrophoresis confirmed that the protein was indeed expressed in a single-chain (“SC”) form, as revealed by a major band migrating with an apparent molecular weight of about 200 kDa. This band was seen in either the absence or presence of reducing agent. See e.g., lanes SC (−) and SC (+) of the Coomassie Brilliant Blue-stained gel in FIG. 8C.

Nicking of this single chain protein (and removal of the His₆ tag) was achieved by incubation of the protein with biotinylated thrombin (1 unit/mg of toxin) at 22° C. for 3 h; the thrombin protease is then removed by treating the sample with streptavidin immobilized on agarose. Two bands (not well resolved by SDS-PAGE due to the similarity in mobility of the two protein chains) having apparent molecular weight of about 100 K appear after thrombin treatment of the protein in samples run on an SDS-PAGE gel under reducing conditions; the ˜200 K band is not seen under these conditions, but is present in gels run under non-reducing conditions, while the ˜100 KDa bands are absent in these latter samples. See e.g., lanes DC (−) and DC (+) of the Coomassie Brilliant Blue-stained gel in FIG. 8C. The ˜100 K bands are believed to represent both the LC/B-LC/A and the HC/A chains, which have small difference in sizes.

Rat cultured cerebellar granule neurons (CGNs) were incubated with the thrombin-treated LC/B-BoNT/A at 5-fold serially diluted concentrations from 0.32 pM to 5000 pM. After 24 hours' incubation at 37° C. with LC/B-BoNT/A, cells were then harvested and subjected to SDS-PAGE and Western blotting, using a) an anti-SNAP-25 antibody recognising both intact SNAP-25 and the large cleavage product of treatment with LC/A, and b) an anti-VAMP2 antibody picking up the intact version. An anti-syntaxin 1 antibody was used to detect the SNARE protein syntaxin 1, which was used as a positive internal loading control. Representative Western blot (FIG. 8D) and quantitative data (FIG. 8E) from multiple blots show that LC/B-BoNT/A cleaved SNAP-25 as well as VAMP2; however, the VAMP2 was cleaved effectively at higher concentrations of the LC/B-BoNT/A. While not wishing to be limited by theory, this result may arise from sequestration of the composite toxin to the membrane through the LC of BoNT/A that would lower VAMP cleavage [Fernández-Salas et al, Proc. Natt. Acad. Sci. USA. 2004, 101(9):3208-3213].

Example 10

As illustrated by the positive functional results from LC/E-BoNT/A (two active proteases recognising two different sequences of same substrate) and LC/B-BoNT/A (two proteases cleaving two different substrates), and in view of the disclosure of this patent application, one of ordinary skill in the art will be aware that additional examples of the present invention may involve compositions and methods for creating various other multi-endopeptidase therapeutics by combination of different Clostridial neurotoxins or Clostridial neurotoxin subtypes for inhibiting the release of pain-peptides and neurotransmitters from various nerve types (eg. sensory and sympathetic neurons). Moreover, the activity of the multi-endopeptidase toxin would indirectly block the activation by such mediators of cytokine-releasing cells.

For example, a single therapeutic which inactivates all three SNARE proteins is created by recombinant fusion of the light chain of BoNT/D (LC/D) to the N-terminus of BoNT/C1 via a linker (see FIG. 9). Briefly, a nucleic acid encoding the LC/D endopeptidase is inserted “in-frame” in LC/E-BoNT/A to replace LC/E. The synthetic gene encoding LC/D is designed to have codons optimised for optimal expression in E. coli. The resultant plasmid encodes an intermediate protein comprising LC/D-BoNT/A.

Subsequently, a synthetic gene encoding BoNT/C1 (like the BoNT/A construct, with a thrombin cleavage site in its loop region) is used to replace the BoNT/A gene in LC/D-BoNT/A to yield a final nucleic acid construct comprising an LC/D-BoNT/C1 open reading frame. The expressed, purified and nicked LC/D-BoNT/C1 therapeutic will have ability to inactive VAMP 1-3 by cleavage with LC/D; the LC/C1 protease will cleave syntaxin 1-3 and SNAP-25. This molecule will be suitable for the treatment of chronic inflammatory and neuropathic pain.

Example 11

A 60 year-old man presents with severe chronic joint pain in the left hip, and has difficulty walking. Following examination, the patient is diagnosed with rheumatoid arthritis of the acetabulofemoral (hip) joint.

The patient is administered the Clostridial neurotoxin derivative LC/E-BoNT/A an effective dose by injection directly into both the femoral ganglion and the sciatic ganglion. The gene construct is made as described above and the Clostridial toxin derivative is affinity purified following the expression thereof using the His₆ tag (SEQ ID NO: 15), following by ion exchange chromatography and thrombin nicking before use.

Within 48 hours, there is notable improvement in the extent and acuteness of pain, and within one week the patient is able to walk with little difficulty.

Although aspects of the present invention have been described with reference to the disclosed embodiments, one skilled in the art will readily appreciate that the specific examples disclosed are only illustrative of these aspects and in no way limit the present invention. Various modifications can be made without departing from the spirit of the present invention. Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent. Furthermore, any composition or apparatus of the invention will be understood to comprise, consist essentially of, or consist of one or more element of the claim, and additionally, each and every element not specifically included as an element of a claim shall be considered to have basis herein to be specifically excluded in a negative limitation from that claim.

Any and all patents, publications, patent applications, and nucleotide and/or amino acid sequences referred to by accession numbers cited in this specification are hereby incorporated by reference as part of this specification in its entirety. 

We claim:
 1. A composition comprising a clostridial neurotoxin derivative, said clostridial neurotoxin derivative comprising a polypeptide including: a) a binding domain, b) a translocation domain, and c) a first active endopeptidase domain derived from a clostridial neurotoxin BoNT/A subtype, and d) a second active endopeptidase domain derived from a clostridial neurotoxin BoNT/E subtype.
 2. The composition of claim 1 wherein said binding domain, translocation domain, first endopeptidase domain, and second endopeptidase domain are comprised in a single polypeptide chain.
 3. The composition of claim 2 wherein said polypeptide further comprises a selective endopeptidase cleavage site located between a first region comprising said binding domain and said translocation domain, and a second region comprising said first endopeptidase domain and second endopeptidase domain.
 4. The composition of claim 1 wherein said binding domain, translocation domain, first endopeptidase domain, and second endopeptidase domain are comprised in more than one polypeptide chain.
 5. The composition of claim 4 wherein at least two of said more than one polypeptide chains are linked by a disulphide bond.
 6. The composition of claim 1 comprising a first polypeptide chain comprising said binding domain and said translocation domain, and a second polypeptide chain comprising said first endopeptidase domain and second endopeptidase domain.
 7. The composition of claim 5 comprising a first polypeptide chain comprising said binding domain and said translocation domain, and a second polypeptide chain comprising said first endopeptidase domain and second endopeptidase domain.
 8. The composition of claim 1 wherein the binding domain and translocation domain are derived from Clostridial neurotoxin BoNT/A.
 9. The composition of claim 8 comprising a first amino acid sequence comprising a first protease cleavage site located between the translocation domain and the first endopeptidase domain.
 10. The composition of claim 8 further comprising: a) a polyhistidine amino acid sequence located on the carboxyl terminal side of the binding domain, or at the amino-terminus of the said second endopeptidase domain; b) a first amino acid sequence comprising a first protease cleavage site located between the translocation domain and the first endopeptidase domain; and c) a second amino acid sequence comprising a second protease cleavage site located between said second endopeptidase domain and the polyhistadine amino acid sequence, or between said binding domain and the polyhistidine amino acid sequence.
 11. A method for the treatment of chronic pain comprising administering a therapeutic composition comprising a clostridial neurotoxin derivative, said clostridial neurotoxin derivative comprising a polypeptide including: a binding domain, a translocation domain, a first active endopeptidase domain derived from a clostridial neurotoxin BoNT/A subtype, and a second active endopeptidase domain derived from a clostridial neurotoxin BoNT/E subtype.
 12. The method of claim 11 wherein said chronic pain is selected from the group consisting of inflammatory nociceptive pain and neuropathic pain.
 13. The method of claim 12 wherein said chronic pain is neuropathic pain.
 14. The method of claim 13, wherein said neuropathic pain is selected from the group consisting of a cancer pain, post-operative pain, allodynia, post-herpetic neuralgia, irritable bowel syndrome, and other visceral pain, bone pain, peripheral neuropathy, circulatory system-affiliated pain, and headache pain.
 15. The method of claim 12 wherein said chronic pain is inflammatory nociceptive pain.
 16. The method of claim 12 wherein said chronic pain is arthritis pain.
 17. The method of claim 11 wherein the binding domain and translocation domain of said therapeutic composition are derived from a Clostridial neurotoxin BoNT/A subtype.
 18. A clostridial neurotoxin derivative comprising: a) a first active clostridial toxin-derived endopeptidase domain which cleaves a SNARE protein under physiological conditions and has an enzymatic half-life of 10 days or greater when injected into mouse gastrocnemius muscle under substantially physiological conditions; b) a second active clostridial toxin-derived endopeptidase domain; c) a clostridial toxin-derived translocation domain which facilitates the movement of said first endopeptidase domain across a cellular membrane into the cytosol under physiological conditions; and d) a clostridial toxin-derived functional binding domain, where said neurotoxin derivative blocks the release of pain-mediators evoked by capsaicin from cultured rat sensory neurons to a greater extent than does BoNT/A alone.
 19. The neurotoxin derivative of claim 18, wherein both said first and second Clostridial toxin-derived endopeptidase domains are derived from a C. botulinum neurotoxin.
 20. The neurotoxin derivative of claim 19, wherein both said first and second Clostridial toxin-derived endopeptidase domains are derived from a different Clostridial neurotoxin subtype. 